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SIR2 calls upon the ER
Resveratrol induces longevity in C. elegans through the action of SIR2. Recently published work shows that resveratrol
induces genes of the unfolded protein stress response of the endoplasmic reticulum. Paradoxically, these stress genes
are repressed by SIR2, suggesting that resveratrol increases life span by inhibiting this SIR2 action.
Tronche, F., Kellendonk, C., Reichardt, H.M., and DOI 10.1016/j.cmet.2005.10.001In past, simpler times, the FOXO tran-
scription factor encoded by daf-16 was
recognized as the common denominator
of C. elegans aging regulation. Func-
tional DAF-16 was found essential for
longevity extension in various settings,
including mutants of insulin/IGF recep-
tor (daf-2) and its signaling partners,
germline stem cell ablation, and overex-
pression of the histone deacetylase
(HDAC) encoded by sir-2.1 (Hekimi and
Guarente, 2003). Small polyphenolic com-
pounds such as resveratrol and fisiten
were found to increase deacetylation by
SIR2 in vitro and to increase life span in
a sir2-dependent manner in yeast, C. ele-
gans, and Drosophila melanogaster (Ho-
witz et al., 2003; Wood et al., 2004). Fur-
thermore, mammalian SIRT was seen to
interact with various transcription fac-
tors including FOXO3a to modulate the
balance between cell survival and apo-
ptosis (Lombard et al., 2005). All roads,
as it were, led to FOXO, and resveratrol
by activating SIR proteins would induce
FOXO-dependent mechanisms to retard
aging (Figure 1A).
In the newest issue of Developmental
Cell, Viswanathan, Guarente, and col-
leagues (Viswanathan et al., 2005) test
the FOXO premise. Remarkably they re-
port that resveratrol increases C. ele-
gans survival even in daf-16 mutants.
Furthermore, resveratrol fails to increase
survival in double mutants of sir-2.1 and
daf-16, and while overexpression of sir-
2.1 alone extends life span, resveratrol
treatment amplifies this even further,
producing worms that live up to a prodi-
gious 60 days. Thus, as reported, resvera-
trol extends life span with sir-2.1 but sur-
prisingly the pathway of the action
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aCELL METABOLISM : NOVEMBER 2005ppears independent of how sir-2.1 af-
ects survival with daf-16.
To uncover the mechanism of this un-
xpected sir-2.1 pathway, Viswanathan
t al. examined genomic message pro-
iles from resveratrol-treated and control
orms. One standout family induced by
esveratrol involved genes encoding a
rion-like Q/N-rich domain (pqn) and its
bu subgroup (activated in blocked un-
olded protein response). The products
f these genes are detected in stressed
ndoplasmic reticulum when there is
alfunction of the canonical unfolded
rotein response (UPR); they may also
perate concurrently with the UPR in
ndefined ways (Urano et al., 2002). In
eneral, different stress conditions can
ffect cell survival through ER responses
hat mediate commitment to apoptosis,
rotective functions of membrane and
rotein biogenesis, and even the activa-
ion of the proinflammation/innate im-
une response (Kaufman, 1999). By ac-
ivating the pqn/abu system, resveratrol
ay elicit a subset of maintenance re-
ponses adapted for survival under
pecific conditions of ER stress. If
esveratrol extends life span specifically
ecause it induces survival conferred by
qn/abu genes, depletion of their mes-
age should block the drug’s survival
enefit. As predicted, RNAi against pqn/
bu candidates reduced or, in the case
f abu-11, completely eliminated the
urvival gain conferred by resveratrol.
ot only is abu-11 necessary for resver-
trol to extend life span, in a wild-type
ackground its transgenic overexpres-
ion is sufficient to increase survival.
To this point the traditional view of
ging regulation through resveratrol ap-
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gears bloodied but alive. First, sir-2.1
ut not daf-16 is required for resveratrol
o extend life span. Second, pqn/abu
enes of the ER affect survival and are
equired for resveratrol to extend life
pan. We might anticipate then that SIR-
.1 is a positive transcriptional regulator
f pqn/abu genes and all the more so
hen it is activated by resveratrol. When
ested, however, this deduction fails. In
ir-2.1 mutants there was dramatically
ore rather than less abu-11 message,
nd this abundance was not changed by
esveratrol treatment. In a symmetric
xperiment, sir-2.1 overexpression de-
reased the message abundance of
any pqn/abu transcripts. The pqn/abu
enes induced by resveratrol are unex-
ectedly repressed by SIR-2.1.
A very different model is required to
ake all these facts coherent. Viswana-
han et al. propose that SIR-2.1 reduces
qn/abu gene expression and resver-
trol blocks this process (Figure 1B).
esveratrol extends life span because it
ermits expression of PQN/ABU that is
ormally inhibited by SIR-2.1, an action
hat is independent of daf-16. The ap-
eal of this model lies in its ability to ac-
ount for most of the dozen or so novel
bservations. On the other hand, several
esults present continuing paradoxes.
Since expression of abu-11 is suffi-
ient to extend life span and SIR-2.1 is
easoned to be a suppressor of pqn/
bu, why doesn’t mutation of sir-2.1 in-
rease life span, especially since abu-11
s elevated? Likewise, resveratrol is
hought to inhibit repression of pqn/abu
y SIR-2.1, but resveratrol treatment re-
uires sir-2.1 to induce exceptional lon-
evity. Viswanathan et al. suggest that281
P R E V I E W SFigure 1. Models of resveratrol regulation of aging: Past, present, future?
A) Past. Insulin signaling through DAF-2 and resveratrol-activated SIR2 converge on the DAF-16 transcription
factor to extend life span.
B) Present. SIR2 has multiple outputs. Resveratrol inhibits SIR2 repression of longevity mechanisms from the
ER independent of the effects of SIR2 via DAF-16.
C) Future? Resveratrol affects factors at promoter complexes including coactivators (CoA), corepressors
(CoR), nuclear hormone receptors (NHR), and transcription factors (TF). Resveratrol activates SIR2; the effect
of increased deacetylation on gene expression depends on the promoter’s context.
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2SIR-2.1 activates a least one other lon-
gevity-mediating pathway. Thus, when
resveratrol represses the SIR-2.1 inhibi-
tion of pqn/abu, SIR-2.1 remains active
to induce the other pathway, which to-
gether with PQN/ABU increases sur-
vival.
Transgenic overexpression of sir-2.1
contributes to a different conundrum.
This represses pqn/abu yet such worms
are long-lived, and resveratrol treatment
further increases this longevity. If resver-
atrol binds to and inhibits SIR-2.1, as
proposed, resveratrol should inhibit the
daf-16-dependent benefit of added SIR-
2.1. To explain how SIR-2.1 remains ef-
fective, Viswanathan et al. propose that
protein substrates determine the out-
come of resveratrol binding to SIR-2.1.
This could explain the variation among
in vitro SIR-2.1 activation assays with
different substrates. In the future we
need in vivo acetylation assays with
SIR-2.1-specific targets. It also remains
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b282mportant to determine the endogenous
olecules of animal cells that may re-
ress or activate SIR-2.1 and how resver-
trol may interfere with or enhance their
nteraction with SIR-2.1.
Finally, resveratrol may increase or de-
rease transcription even if it only acti-
ates SIR-2.1 deacetylation (Figure 1C).
DACs modulate many components of
romoters and whether the end result is
ctivation or repression of transcription
epends on the details, an example be-
ng NHR complexes where transcription
actors, coactivators, and corepressors
re all modified by HDACs (Hu and La-
ar, 2000). Depending on the combina-
ion of cofactors, by activating SIR-2.1
esveratrol could either induce or re-
ress a gene. Furthermore, resveratrol
odifies many other proteins. For in-
tance, it directly inhibits specific cyto-
hrome P450 enzymes (Chang et al.,
001) and the RIP and TBK of Toll recep-
ors complexes (Youn et al., 2005). Nota-
ly, resveratrol is a competitive agonist
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Df the estrogen receptor (Gehm et al.,
997). If these sorts of actions directly
r indirectly affect the promoter com-
lexes of pqn/abu genes, they can
pecify the transcriptional outcome of
ctivated SIR-2.1. The emerging longev-
ty network with daf-16, sir-2.1, ER, and
IR-activating compounds is indeed
omplex. Given current progress, these
esults should become coherent in the
ear future, and then the past will once
gain be proven to have been simpler
imes.
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